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Noradrenergic responses of peripheral organs to cyclophosphamide in mice

Abstract
To determine if the chemotherapeutic drug cyclophosphamide influences the activity of the
sympathetic nervous system, the effects of cyclophosphamide on norepinephrine concentration
in the heart, adrenal gland, spleen, and thymus gland were evaluated. Male BALB/cByJ mice
were administered a single injection of cyclophosphamide (15, 50, or 100 mg/kg, i.p) or salinevehicle. Organs were collected 72 or 120 h after injection and norepinephrine concentrations
were determined by high pressure liquid chromatography with electrochemical detection.
Cyclophosphamide reduced spleen, thymus gland, and heart mass while also elevating spleen
and thymus gland norepinephrine concentrations (both pmoles/mg tissue and pmoles/mg protein)
in a dose- and time-dependent manner. Norepinephrine concentrations in heart and adrenal gland
were not altered by cyclophosphamide at any drug dose or time point. Dose- and time-dependent
cyclophosphamide-mediated changes in peripheral norepinephrine levels in the spleen and
thymus gland are interesting because subjects administered cyclophosphamide may be more
susceptible to opportunistic infections, not only because the drug is antineoplastic, but also
because the drug alters nervous system-immune system communication and the neurochemical
milieu in which surviving cells interact.
Introduction
Cyclophosphamide is a nitrogen mustard used to inhibit the growth of some tumors, to
treat various autoimmune disorders, and to prevent rejection of organ transplants (Singer and
McCune, 1998; Colvin, 1999). Most research involving cyclophosphamide has examined the
cells targeted by cyclo- phosphamide and the mechanisms through which cyclophosphamide
influences these targets. These studies show that cyclophosphamide is activated by liver
cytochrome P450 and the resulting bioactive metabolites prevent mitosis of tumor cells or
myeloid cells by alkylating DNA and preventing cell division (Ludeman, 1999).

Little work has investigated non-cytotoxic in vivo consequences of cyclophosphamide
administration. It is not known to what extent cyclophosphamide alters factors that could
influence the activity of cells that survive initial cyclophosphamide exposure or if organs
without proliferating cells are responsive to this cytotoxic drug. Changes in the chemical milieu
from cyclophosphamide administration could contribute to the side-effects associated with
cyclophosphamide treatment (such as fatigue, nausea, headaches, or taste aversion). In addition,
non-cytotoxic effects of cyclo- phosphamide could contribute to the physiological mechanisms
underlying reports that behavioral conditioning, psychological stress, and environmental (e.g.,
seasonal) factors influence the ability of cyclophosphamide to inhibit tumor growth and suppress
rejection of tissue allografts (Gorczynski, 1990; Perissin et al., 1991; Giraldi et al., 1994; Perissin
et al., 1996; Zorzet et al., 1998, 2002). Indeed, in recent studies, cyclophosphamide has been
shown interact with anti-angiogenic drugs to reduce tumor metastasis (Mauceri et al., 2002) and
to improve the efficacy of cytochrome P-450 based gene therapy (Jounaidi and Waxman,
2001). It is possible that cyclophosphamide-mediated changes in the neurochemical milieu could
play a role in the mechanisms subserving these observations.
This experiment investigated the possibility that cyclophosphamide might alter the
noradrenergic environment of organs innervated by the sympathetic nervous system.
Norepinephrine concentrations following cyclophosphamide treatment were evaluated in organs
with ongoing cell proliferation (spleen and thymus gland) and in organs not typically associated
with cell proliferation (heart and adrenal gland). These experiments sought to confirm and extend
previous observations that cyclophosphamide induces dose- and time-dependent changes in the
norepinephrine content of the spleen (Karp and Szczytkowski, 2003). We considered two
possible outcomes. First, cyclophosphamide might alter norepinephrine concentrations in all

peripheral organs innervated by the sympathetic nervous system. Alternatively,
cyclophosphamide might only alter norepinephrine concentrations in organs with a high
percentage of proliferating cells.
Materials and methods
Animals
Male BALB/cByJ mice (n = 64, aged 3–5 wks, The Jackson Labs, Bar Harbor, ME) were
the subjects of these experiments. Mice were housed 4 per cage in standard shoe box cages and
allowed to acclimate to our colony for 2–3 wks prior to the start of an experiment. Food (Purina
rodent chow #5015) and water were available at all times. All the mice in a cage always received
the same treatment. The Rider
University Institutional Animal Care and Use Committee approved all animal procedures
in accordance with the guidelines established by the National Institutes of Health.
Injections
Cyclophosphamide (Sigma-Aldrich, St. Louis, MO) was solubilized in ethanol, diluted in
sterile filtered phosphate buffered saline (GIBCO, Carlsbad, CA), and administered by peritoneal
injection (in a total volume of 500 Al). Vehicle-treated animals received an equal volume of the
phosphate buffered saline-ethanol solution. The body mass of the mice was determined 3 days
before cyclophosphamide or vehicle injections.
Organ harvest and norepinephrine measurements
Mice were killed by rapid cervical dislocation either 72 or 120 h after injection of
cyclophosphamide or vehicle (time course selected from Karp and Szczytkowski, 2003). Spleen,
thymus gland, heart, and one adrenal gland were immediately harvested, weighed, placed in cold
0.1M HClO4 (spiked with an internal standard of 3,4-dihydroxybenzylamine to a final

concentration 0.25 AM), and stored at 80 8C until assayed. At the time of assay,
samples were homogenized (Sonic Dismembrator, Artek Systems Corporation, Farmingdale,
NY), centrifuged and aliquots of the supernatants were combined with sodium phosphate
buffer (pH 6.1) and 1.5M Tris/EDTA buffer (pH 8.6). Acid-washed alumina was added to each
sample and norepinephrine was extracted by shaking for several minutes. The alumina was
washed with distilled water, placed into a clean microfilter and the water was removed by
centrifugation. Norepinephrine was eluted off the alumina by adding 0.1 M HClO4. Sample
extracts in the 0.1 M HClO4 were stored on ice until they were manually injected into the highperformance liquid chromatography (HPLC) machine.
The HPLC system consisted of a Varian ProStar programmable pump and a Varian Res
Elut C18 reverse-phase column (150 mm x 4.6, 5 A) located in a temperature controlled housing
(27 8C) with the electrochemical detector (Varian Star 9080). The system was operated at a flow
rate of 1.0 ml/min with the detector potential set at 0.75 V versus an Ag-AgCl reference
electrode. The mobile phase buffer consisted of 0.33 M citrate, 0.67 M phosphate (pH 4.5) with
sodium octyl sulfate (1.2 mM) and 12% methanol. The signal from the detector was recorded by
a PC computer using Varian Star Chromatography software (Star Chromatography, version 5).
The Varian Star Chromatography software measured area under each peak and compared the
value obtained to the internal standard (5 pmoles of 3,4-dihydroxybenzylamine).
Protein assays
The protein content of each sample was determined using a commercially available
protein assay kit (Pierce, Rockford, IL). This assay is based on the bicinchroninic acid method
for the colorimetric detection and quantification of total protein. Directions recommended by the
supplier for conducting this assay on 96-well plates were followed and the assay reaction was

read using a plate reader at 570 nm (SpectraCount Microplate Photometer, Packard Bioscience
Company, Meriden, CT). Protein content was read off a standard curve of known amounts of
bovine serum albumin.
Data analysis
Data were evaluated at each time point by ANOVA followed by the Student-NewmanKeuls post-hoc test (SPSS for Windows version 11.0, SPSS Inc., Chicago, IL). Treatment effects
were considered significant at p V 0.05. All data are presented as mean F SEM.
Results
Norepinephrine concentrations in spleen
Spleen mass was reduced by cyclophosphamide administration in a dose-dependent
manner (Fig. 1A). At the 72 hr time point, all three cyclophosphamide doses decreased spleen
mass (F(3,31) = 50.1, p b.01); among the cyclophosphamide-treated groups, the mice
administered 100 mg/kg exhibited smaller spleens compared to the mice administered 50 mg/kg
and mice in the 50 mg/kg condition exhibited smaller spleens than mice in the 15 mg/kg group.
At the 120 hr time point, cyclophosphamide-mediated reductions in spleen mass persisted, as all
cyclophosphamide treatments reduced spleen mass compared to saline-vehicle (F(3,31) = 18.5, p
b .01). Amongst the cyclophosphamide-treated conditions at 120 h, mice administered 100
mg/kg cyclophosphamide exhibited smaller spleens than the mice in the 15 and 50 mg/kg
groups.
Cyclophosphamide elevated the concentration of norepinephrine (pmoles per mg spleen)
in a dose- and time-dependent manner (Fig. 1B). At 72 h (F(3,30) = 15.6, p b .01), mice in the 50
and 100 mg/kg conditions showed a greater concentration of norepinephrine in comparison to

mice the saline-vehicle and 15 mg/kg conditions. At 120 h no statistical differences were
observed between the saline-vehicle and any of the cyclophosphamide-treated conditions.
The concentration of norepinephrine (pmoles per mg protein) in the spleen was also
elevated by cyclophosphamide in a dose- and time-dependent manner (Fig. 1C). At the 72 hr
time point (F(3,30) = 15.2, p b .01), spleens from the mice administered 50 and 100 mg/kg
cyclophosphamide exhibited significantly more norepinephrine per mg protein than the salinevehicle and 15 mg/kg groups. By 120 h after injection no statistical differences were observed
between the saline-vehicle and any of the cyclophosphamide-treated groups.
The total amount of norepinephrine per spleen was calculated by multiplying the
concentration of norepinephrine per mg spleen x the mass of the spleen (Table 1). These
calculations allow an estimate of the effects of cyclophosphamide on norepinephrine turnover.
These analyses revealed neither an effect of cyclophosphamide dose (0, 15, 50, 100 mg/kg) nor
an effect of time (72 or 120 h) on the total norepinephrine content of the spleen.
Norepinephrine concentrations in thymus
Thymus mass was reduced by cyclophosphamide administration in a dose-dependent
manner (Fig. 2A). At the 72 hr time point, all three cyclophosphamide doses significantly
decreased thymus mass compared to saline-vehicle (F(3,31) = 39.6, p b .01). The magnitude of
these changes at 72 h were dose- dependent as the 100 and 50 mg/kg groups were less than the
15 mg/kg group, and the 15 mg/kg group was less than only the saline-vehicle treated group. At
the 120 hr time point, all cyclophosphamide doses

Fig. 1. Effects of cyclophosphamide (CY) on spleen mass (mg, 1A), norepinephrine (NE)
per mg spleen (pmoles/mg, 1B), and norepinephrine per mg protein in the spleen (pmoles/mg
protein, 1C). Spleens were harvested 72 or 120 h after an i.p. injection of 0, 15, 50 or 100 mg/kg
cyclophosphamide. Asterisk (*) indicates significantly different from saline at same time point.
All values are mean F s.e.m. (n = 8/group).
reduced thymus mass compared to saline-vehicle (F(3,31) = 12.5, p b .01) and the
cyclophosphamide- treated conditions did not differ from each other.
Cyclophosphamide elevated the concentration of norepinephrine (pmoles per mg thymus)
in a dose- and time-dependent manner (Fig. 2B). At 72 h (F(3,31) = 21.0, p b .01), thymus
norepinephrine concentration was elevated among mice in the 50 and 100 mg/kg groups
compared to the saline- vehicle and 15 mg/kg groups. The 100 mg/kg group was also elevated
compared to the 50 mg/kg group at 72 h. Cyclophosphamide mediated elevations in
norepinephrine per mg thymus persisted 120 h after a single cyclophosphamide injection
(F(3,31) = 6.0, p = .03) with only the mice treated with 100 mg/kg cyclophosphamide showing
elevated thymus norepinephrine concentrations compared to saline-vehicle.
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18
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Total norepinephrine content was calculated as norepinephrine per mg tissue x the mass of each organ. These calculations estimate
the effects of cyclophosphamide (CY) on norepinephrine turnover in each of the indicated organs. Asterisk (*) indicates significantly different
from saline at same time point. All values are mean pmoles per organ F s.e.m. (n = 8/group).

Total norepinephrine content was calculated as norepinephrine per mg tissue x the mass
of each organ. These calculations estimate the effects of cyclophosphamide (CY) on
norepinephrine turnover in each of the indicated organs. Asterisk (*) indicates significantly
different from saline at same time point. All values are mean pmoles per organ F s.e.m. (n =
8/group).
Fig. 2. Effects of cyclophosphamide (CY) on thymus gland mass (mg, 2A),
norepinephrine (NE) per mg thymus (pmoles/mg, 2B), and norepinephrine per mg protein in the
thymus (pmoles/mg protein, 2C). Thymus glands were harvested 72 or 120 h after an i.p.
injection of 0, 15, 50 or 100 mg/kg cyclophosphamide. Asterisk (*) indicates significantly
different from saline at same time point. All values are mean F s.e.m. (n = 8/group).

The concentration of norepinephrine (pmoles per mg protein) in the thymus was also
elevated by cyclophosphamide in a dose- and time-dependent manner (Fig. 2C). At 72 h (F(3,31)
= 12.6, p b .01), the 50 and 100 mg/kg groups exhibited significantly more norepinephrine per
mg protein than the saline and 15 mg/kg groups. An effect of cyclophosphamide on
norepinephrine per mg protein in the thymus endured at 120 h (F(3,31) = 6.5, p b .01) but by this
time only the 100 mg/kg group remained elevated compared to the saline group.
A single injection of cyclophosphamide elevated the total amount of norepinephrine
(pmoles per thymus, Table 1) at 72 (F(3,31) = 5.9, p b .01) and 120 (F(3,31) = 4.2, p = .01) h
after injection. At
72 h, thymus glands from both the 50 and 100 mg/kg groups exhibited
increases in total norepinephrine content compared to the saline-vehicle and 15 mg/kg group. At
120 h, only thymus glands from the 100 mg/kg group still exhibited elevations in total
norepinephrine content compared to saline-vehicle.
Norepinephrine concentrations in heart
Cyclophosphamide-mediated reductions in heart mass were evident 72 h (F(3,31) = 3.2, p
= .04) and 120 h (F(3,31) = 2.9, p = .05) after injection; 100 mg/kg lowered the total mass of the
heart compared to
Fig. 3. Effects of cyclophosphamide (CY) on heart mass (mg, 3A), norepinephrine (NE)
per mg heart (pmoles/mg, 3B), and norepinephrine per mg protein in the heart (pmoles/mg
protein, 3C). Hearts were harvested 72 or 120 h after an i.p. injection of 0, 15, 50 or 100 mg/kg
cyclophosphamide. Asterisk (*) indicates significantly different from saline at same time point.
All values are mean F s.e.m. (n = 8/group).

saline-vehicle and to the other cyclophosphamide-treated conditions (Fig. 3A). There
were no effects of cyclophosphamide treatment on any measure of norepinephrine concentration
(Fig. 3B–C) or total norepinephrine per heart (Table 1).
Norepinephrine concentrations in adrenal gland
Adrenal gland mass, norepinephrine per mg adrenal tissue, norepinephrine per mg protein
(Fig. 4A– C), and the total amount of norepinephrine per adrenal gland (Table 1) were not
altered by cyclophosphamide at either 72 or 120 h after injection.
Fig. 4. Effects of cyclophosphamide (CY) on adrenal gland mass (mg, 4A),
norepinephrine (NE) per mg adrenal gland (pmoles/ mg, 4B), and norepinephrine per mg protein
in the adrenal gland (pmoles/mg protein, 4C). Adrenal glands were harvested 72 or 120 h after an
i.p. injection of 0, 15, 50 or 100 mg/kg cyclophosphamide. Asterisk (*) indicates significantly
different from saline at same time point. All values are mean F s.e.m. (n = 8/group).
Discussion
These data confirm and extend observations that cyclophosphamide induces dose- and
time- dependent elevations in norepinephrine concentration in the spleen (Karp and
Szczytkowski, 2003). We additionally demonstrate that cyclophosphamide elevates
norepinephrine concentration in the thymus gland but not in the heart or adrenal gland. It appears
therefore that cyclophosphamide does not cause a widespread activation of the sympathetic
nervous system as measured by changes in norepinephrine concentration. Instead,
cyclophosphamide appears to alter the amount of norepinephr- ine available to influence cell-cell
interactions in tissues associated with immune system function. It is therefore possible, though
not shown here, that given the effects of norepinephrine on cells of the immune system, that
cyclophosphamide is immunomodulatory in addition to being cytotoxic and immunosuppressive.

It is possible that cyclophosphamide-induced reductions in organ mass are responsible for
cyclophosphamide-induced elevations in organ norepinephrine content. However reductions in
organ mass were not always associated with elevations in norepinephrine in the spleen, thymus
gland, or heart (see Figs. 1–3). Additional experiments are needed to determine the
mechanism(s) through which changes in organ mass and norepinephrine concentration are
associated. It is possible that cyclophosphamide-mediated reductions in organ mass might occur
from a transient drug-induced alteration of cell proliferation, from changes in cell metabolism,
from changes in vascular tone of the target organs, changes in cell migration, or from another
mechanism. It is also possible that cyclophosphamide-induced reduction in heart mass may be
associated with the myocarditis and cardiomyopathy associated with some chemotherapeutic
interventions (Remme, 1998; Sparano, 1999; Calabrese et al., 2003; Kang, 2003).
As the migration of lymphocytes into the peripheral circulation is a well-known effect of
norepinephrine (Kohm and Sanders, 2001; Madden, 2003), it is possible, though not proven here,
that norepinephrine stimulated lymphocyte migration from the spleen, the thymus gland, and to a
lesser extent the heart without causing damage to surviving tissues. This possibility is supported
by a report that examined the effects of cyclophosphamide on the sympathetic nerve fibers in the
spleen; Carlson and colleagues (Carlson et al., 1987) reported that cyclophosphamide increases
the density of sympathetic nerve fibers around the arterioles of the spleen and, consistent with
our results, that these fibers maintained organ norepinephrine levels even as the number of
lymphocytes in the spleen decreased (Carlson et al., 1987; Karp and Szczytkowski, 2003). To
our knowledge, the structural consequences of cyclophosphamide administration on the
sympathetic nerve fibers of the thymus gland have not been directly evaluated, though
cyclophosphamide appears to stimulate apoptosis in the thymus (Ishiyama et al., 1999) as well as

reduce the number of PNA+/CD3- and double positive (CD4+, CD8+) thymocytes (Miyauchi et
al., 1990).
The current experiments do not allow us to determine if cyclophosphamide directly or
its in vivo metabolites (Ludeman, 1999; Roy et al., 1999) are responsible for cyclophosphamideinduced elevations in norepinephrine concentrations in the spleen and thymus gland. In order to
inhibit the proliferation of tumor cells, cyclophosphamide acts as a prodrug and is catalyzed by
hepatic P450 enzymes to yield cytotoxic phosphoramide mustards (Anderson et al., 1995; Roy et
al., 1999). It

is not yet determined if cyclophosphamide-induced elevations in

norepinephrine concentration alter the activity of P450 enzymes or if elevations in
norepinephrine concentration alter other aspects

of cyclophosphamide metabolism. It is

interesting however that others report that cyclophosphamide can improve the efficacy of
cytochrome P-450 based gene therapy (Jounaidi and Waxman, 2001).
What role cyclophosphamide and/or cyclophosphamide-induced changes in
norepinephrine have on specific cells not targeted by the drug or its metabolites has not been
elucidated. The effects of norepinephrine and beta-receptors on endothelial cells of the blood
vessels (Esler, 2000; Von Kanel and Dimsdale, 2000) make it tempting to speculate that the
noradrenergic effects of cyclo- phosphamide might contribute to the anti-angiogenic and antitumor effects of repeated, low dose cyclophosphamide treatments (Jounaidi and Waxman, 2001;
Man et al., 2002; Mauceri et al., 2002). In regard to the cells of the spleen and thymus gland,
some research suggests in vivo cyclophosphamide administration preferentially depletes B cells
and results in suppression of antibody responses (Austin et al., 1997; Zandvoort et al., 2001).
Other research suggests that cyclophosphamide depletes CD4+ T cells which results in a relative
enlargement of the CD8+ T cell pool (Lacki et al., 1997); such data are consistent with

cyclophosphamide-induced increases in CD8+ cell infiltration of the heart in an animal model of
a parasitic infection (Calabrese et al., 2003). The spleens from cyclophosphamide-treated mice
also contain nitric oxide producing myeloid cells which might contribute to the anti-tumor
actions of cyclophosphamide (Pelaez et al., 2001). Yet, irrespective of the cell types most
affected by cyclophosphamide, it appears as if the drug directly

or indirectly alters the relative

amount of norepinephrine (and perhaps other neurochemicals) available to influence cell-cell
interactions in some of the organs innervated by the sympathetic nervous system.
Cyclophosphamide-mediated changes in norepinephrine could contribute to the sideeffects some- times associated with administration of chemotherapeutic drugs. Norepinephrine is
generally associated with increases in glucose utilization, increases in heart rate and blood
pressure, and central nervous system actions such as motor control, cognition, emotion, memory
processing, and endocrine modulation (Lambert, 2001). Norepinephrine is also known for its
immunoregulatory properties (Elenkov et al., 2000; Bellinger et al., 2001; Kohm and Sanders,
2001; Sanders and Straub, 2002; Madden, 2003). For example, stimulation of norepinephrine
receptors on B cells can drive increases in antibody production (Elenkov et al., 2000; Bellinger et
al., 2001; Kohm and Sanders, 2001; Sanders and Straub, 2002; Madden, 2003). Furthermore,
both antagonism of noradrenergic beta-receptors and sympathectomy attenuated the conditioned
suppression of lymphocyte activity established by pairing a chemotherapeutic drug with
saccharin (Exton et al., 2002). Finally, interactions between cyclo- phosphamide administration
and animal behavior are evidenced in observations that the ability of cyclophosphamide to retard
tumor growth can be reduced by both restraint (Zorzet et al., 1998) and spatial disorientation
(Perissin et al., 1991).
Conclusion

Cyclophosphamide is not merely a cytotoxic compound whose effects are limited to cells
undergoing mitosis. When it is administered by injection, cyclophosphamide and/or its
metabolites can alter the noradrenergic environment of the spleen and thymus gland even though
the sympathetic division of the nervous system is not known as a reservoir of actively
proliferating cells. As a consequence, cyclophosphamide, through alterations in norepinephrine
and perhaps other neurochemicals, has the potential to influence bidirectional interactions
between immunological, neurochemical, and behavioral factors. Cyclophosphamide-induced
changes in the neurochemical environment could contribute to the efficacy or the side-effects of
chemotherapeutic interventions such as lethargy, nausea, vomiting, alopecia, and cognitive
alterations (Schagen et al., 2002; Phillips and Bernhard, 2003). It follows that peripheral nervous
system responses to cyclophosphamide and perhaps other chemotherapeutic drugs should be
considered when treating the side-effects associated with these drugs and perhaps even employed
as potential cofactors in the use of these drugs for chemotherapeutic purposes.
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